Article Information
History
- August 10, 2022.
Article Versions
- You are currently viewing Version 1 of this article (August 10, 2022 - 09:13).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Francis Mwimanzi1,
- Hope R. Lapointe2,
- Peter K. Cheung1,2,
- Yurou Sang1,
- Fatima Yaseen1,
- Rebecca Kalikawe1,
- Sneha Datwani1,
- Laura Burns3,
- Landon Young3,
- Victor Leung4,5,
- Siobhan Ennis1,
- Chanson J. Brumme2,4,
- Julio S.G. Montaner2,4,
- Natalie Prystajecky5,6,
- Christopher F. Lowe3,5,
- Mari L. DeMarco3,5,
- Daniel T. Holmes3,5,
- Janet Simons3,5,
- Masahiro Niikura1,
- Marc G. Romney3,5,*,
- Zabrina L. Brumme1,2,* and
- Mark A. Brockman1,2,*,†
- 1Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6, Canada
- 2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, V6Z 1Y6, Canada
- 3Division of Medical Microbiology and Virology, St. Paul’s Hospital, Vancouver, V6Z 1Y6, Canada
- 4Department of Medicine, University of British Columbia, Vancouver, V6T 1Z3, Canada
- 5Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, V6T 1Z7, Canada
- 6British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, V5Z 4R4, Canada
- ↵†Corresponding Author Contact Information:
Mark A. Brockman, Ph.D., Professor, Faculty of Health Sciences, Simon Fraser University, 8888 University Drive, Burnaby, BC, Canada, V5A 1S6, Tel: 778 782-3341; Fax: 778-782-5927; email: mark_brockman{at}sfu.ca
↵* MAB, MGR and ZLB contributed equally
Posted August 10, 2022.
BRIEF REPORT: Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after three doses of COVID-19 mRNA vaccine
